TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

Multi-drug Resistant Tuberculosis Clinical Trial

— LiMiT  

Official title:

TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00664313
• Other study ID #: CDC-NCHHSTP-5356
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 18, 2008
• Last updated: October 1, 2012
• Start date: April 2009
• Est. completion date: September 2010

Study information

• Verified date: October 2012
• Source: Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationSouth Africa: Medicines Control Council
• Study type: Interventional

Clinical Trial Summary

The antibiotic linezolid when given for the treatment of multi-drug resistant tuberculosis is safe and tolerated at a low dose (600 mg daily) for a limited duration (16 weeks)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Pulmonary tuberculosis with or without extrapulmonary TB with a M. tuberculosis isolate that is confirmed to be resistant to at least rifampin and isoniazid (without regard to prior treatment for TB).

2. A documented positive sputum culture result for M. tuberculosis from a sputum obtained in the four months prior to enrollment.

3. Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 6 months prior to enrollment.

4. Residence within the Durban Functional Region (Durban Metropolitan Area) or Tugela Ferry, Msinga District, KZN, RSA.

5. Age = 18 years.

6. Karnofsky score of > 50 (see section 18.1)

7. Willingness by the patient to attend scheduled follow-up visits and undergo study assessments.

8. Women with child-bearing potential must agree to practice an adequate method of birth control or to abstain from heterosexual intercourse during study therapy. (Standard birth control measures are provided free of charge by public health institutions)

9. Laboratory parameters done within 14 days prior to screening:

1. Serum creatinine level < 2 times upper limit of normal

2. Hemoglobin level = 9.0 g/dL

3. Platelet count of = 80,000/mm3

4. Absolute neutrophil count (ANC) > 1000/ mm3

5. Negative pregnancy test (for women of childbearing potential)

10. Able to provide informed consent or legally authorized representative able to do so if decisionally impaired.

Exclusion Criteria

1. Currently breast-feeding or pregnant.

2. Known allergy or intolerance to linezolid.

3. Planned therapy during the intensive phase of tuberculosis treatment using drugs having unacceptable interactions with linezolid, including dopamine, selective serotonin uptake inhibitors (citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), amitriptyline, bupropion, mirtazepine, levodopa, carbidopa, sinemet, or herbal medications.

4. Significant peripheral neuropathy as evidenced by < 5 seconds of vibratory sense to a 128 Hz tuning fork on either big toe

5. Pain, aching or burning of the feet that interfere with walking or sleep.

6. In the judgment of the physician the patient is not expected to survive for more than 4 weeks.

7. Anticipated surgical intervention for the treatment of pulmonary tuberculosis

8. Visual acuity of 20/200 (6/60 meters) best corrected vision or less.

9. Poor color vision as evidenced by incorrect answers on > four of 12 screening Ishihara plates

10. Participation in another drug trial.

11. The patient has received second line TB drugs for > 7 days immediately prior to enrollment (note: use of first line drugs such as INH, Rifampin, PZA, or ethambutol for > 7 days immediately prior to enrollment is allowed)

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Extensively Drug Resistant Tuberculosis
• Extensively Drug-Resistant Tuberculosis
• Multi-drug Resistant Tuberculosis
• Tuberculosis
• Tuberculosis, Multidrug-Resistant

Intervention

Drug:
• Linezolid
600 mg po daily for 112 doses (16 weeks)
• Placebo
Placebo given daily for 112 doses (16 weeks)

Locations

Country	Name	City	State
South Africa	King George V Hospital	Durban

Sponsors (4)

Lead Sponsor	Collaborator
Centers for Disease Control and Prevention	Columbia University, University of KwaZulu, Yale University

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative rate of serious adverse events - SAEs (measured as the number of SAEs per person days) during the period of study therapy and the four weeks of post-study therapy follow-up.		the period of study therapy (generally 16 weeks) plus the four weeks of post-study therapy follow-up.	Yes
Primary	Proportion of patients in each arm who complete 80% of the proposed regimen (90 doses) within 18 weeks of treatment initiation.		within 18 weeks of treatment initiation	Yes
Secondary	The number of days required to convert to culture negative status in sputum of those in each treatment arm on solid and liquid media, respectively.		first 16 weeks of study therapy	No
Secondary	The proportion of culture-negative patients during the first 16 weeks of therapy (at two week intervals) of linezolid with OBT vs. that of OBT with placebo on solid and liquid media, respectively		first 16 weeks of study therapy	No
Secondary	Time to detection of M. tuberculosis on MGIT for each positive culture for sputum specimens collected every 2 weeks during the first 16 weeks of therapy		First 16 weeks of study therapy	No
Secondary	The occurrence of treatment failure in the first 12 month following initiation of study therapy		first 12 months	No
Secondary	Changes from baseline in assessments for peripheral neuropathy		First 12 months	Yes
Secondary	Changes from baselines in Snellen or Jaeger visual acuity test and Ishihara color plate test results to assess for optic neuropathy		12 months	Yes